| Description | Lalistat 1 is an inhibitor of lysosomal acid lipase (LAL, IC50 = 68 nM) and IgA1 protease for H. influenzae. Lalistat 1 can be used in studies about niemann-pick type C diseases. |
| In vitro | Lalistat 1 (0-100 μM) 剂量依赖性地抑制IgA1P B1和B2，在50 μM时几乎完全抑制，在100 μM时完全抑制[1]。Lalistat 1可减少缺乏NPC1的GM03123人类成纤维细胞中溶酶体样储存库的胆固醇积累[2]。 |
| Target activity | LAL (human):68 nM (IC50) |
| Synonyms | ZINC795230 |
| molecular weight | 298.36 |
| Molecular formula | C12H18N4O3S |
| CAS | 501104-16-1 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | Ethanol: 20 mg/mL DMSO: 45 mg/mL (150.82 mM), Sonication is recommended. DMF: 20 mg/mL |
| References | 1. Rosenbaum, A.I., Rujoi, M., Huang, A.Y., et al. Chemical screen to reduce sterol accumulation in Niemann-Pick C disease cells identifies novel lysosomal acid lipase inhibitors. Biochim Biophys. Acta. 1791(12), 1155-1165 (2009). 2. Rosenbaum, A.I., Cosner, C.C., Mariani, C.J., et al. Thiadiazole carbamates: Potent inhibitors of lysosomal acid lipase and potential Niemann-Pick type C disease therapeutics. J. Med. Chem. 53(14), 5281-5289 (2010). 3. Livia Shehaj, et al. Small-Molecule Inhibitors of Haemophilus influenzae IgA1 Protease.ACS Infect Dis. 2019 Jul 12;5(7):1129-1138. |